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ABSTRACT
Introduction: The objective was to compare 
glycemic control, insulin utilization, and body 
weight in patients with type 2 diabetes (T2D) 
initiated on insulin detemir (IDet) or insulin 
glargine (IGlar) in a real-life setting in the 
Netherlands. Methods: Insulin-naïve patients 
with T2D, starting treatment with IDet or IGlar 
between January 1, 2004 and June 30, 2008, were 
selected from the PHARMO data network. 
Glycemic control (hemoglobin A1c [HbA1c]), 
target rates (HbA1c <7%), daily insulin dose, and 
weight gain were analyzed comparing IDet and 
IGlar for patients with available HbA1c levels 
both at baseline and at 1-year follow-up. Analysis 
of all eligible patients (AEP) and a subgroup of 
patients without treatment changes (WOTC) in 
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the follow-up period were adjusted for patient 
characteristics, propensity scores, and baseline 
HbA1c. Results: A total of 127 IDet users and 
292 IGlar users were included in the WOTC 
analyses. The mean HbA1c dropped from 8.4%-
8.6% at baseline to 7.4% after 1 year. Patients at 
HbA1c goal increased from 9% at baseline to 32% 
for IDet and 11% to 35% for IGlar, which was 
not significantly different (OR 0.75, 95% CI 0.46, 
1.24). Weight gain (n=90) was less among IDet 
users (+0.4kg) than among IGlar users (+1.1kg), 
albeit not significant. The AEP analysis (252 IDet 
+ 468 IGlar users) showed similar results with 
33%-36% at goal (OR 0.81, 95% CI 0.57, 1.16), and 
median daily insulin doses of 25 IU/day (P=0.70). 
Conclusion: There was no significant difference 
between users of IDet and IGlar with respect to 
glycemic control and insulin dose in a real-life 
setting. The low proportion of patients on target 
at baseline may indicate that insulin therapy is 
initiated too late. Moreover, the observation that 
one-third of the patients reached HbA1c target at 
follow-up may indicate that basal insulin analogs 
are not titrated intensively enough.
Keywords: dose; glycemic control; HbA1c; 
insulin detemir, insulin glargine; retrospective 
cohort study; type 2 diabetes; utilization
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INTRODUCTION
Type 2 diabetes (T2D) is a progressive disease, 
which is characterized by increased blood 
glucose levels. Glycemic control is important 
for the prevention of cardiovascular, renal, 
and neurological complications.1-5 To obtain 
glycemic control, patients are initially treated 
with oral antidiabetics (OAD), along with diet 
and exercise management. In the course of the 
disease progression, most patients will require 
exogenous insulin to maintain hemoglobin 
A1c (HbA1c) at target levels. The purpose of 
insulin therapy is to mimic the natural insulin 
secretion and reduce HbA1c in patients with 
elevated levels. In order to delay or prevent 
diabetes-related complications, the goal for 
therapy is “near-normal” glycemia. The Dutch 
general practitioners (GPs) guidelines,6 and the 
new American Diabetes Association/European 
Association for the Study of Diabetes (ADA/EASD) 
consensus algorithm,7,8 which was developed in 
2009, set the general glycemic treatment goal to 
HbA1c <7%.
The two long-acting insulin analogs insulin 
detemir (IDet) and insulin glargine (IGlar) offer 
a prolonged duration of action compared to 
intermediate-acting basal insulin (NPH). In 
patients with T2D, basal insulin can be used 
either as an add-on to OADs, or as part of a basal-
bolus regimen.9,10 The advantage of long-acting 
insulin analogs compared to NPH is reduced risk 
of hypoglycemic events, while providing similar 
HbA1c levels.11-17 Studies have shown that IDet 
and IGlar provide similar glycemic control 
at similar doses.18-20 IDet has demonstrated 
less weight gain compared to both NPH12,16,21 
and IGlar.19,20,22,23
Most of the above-mentioned results are 
obtained in randomized controlled trials 
(RCT), which demonstrate the efficacy of basal 
insulin. However, clinical trials are limited by 
low generalizability of the findings due to the 
controlled study settings. Consequently, there 
may be a discrepancy between the efficacy 
(outcome in RCTs) and effectiveness (outcome 
in real life). Retrospective data analysis using 
real-world healthcare utilization and laboratory 
data can provide additional insights into the 
effectiveness in terms of utilization pattern, 
glycemic outcome, and body weight for IDet 
and IGlar.13,24-26
The objective of this study was twofold. 
Firstly, to compare glycemic control, insulin 
utilization, and body weight in patients with 
T2D initiated on IDet or IGlar in a Dutch real-life 
setting. Secondly, to examine how these real-life 
results correspond with treatment guidelines.
PATIENTS AND METHODS
Data
This retrospective study used the PHARMO 
data network in the Netherlands, which contains 
linked community pharmacy and hospitalization 
data for approximately 3.1 million patients. 
Community pharmacies dispense all outpatient 
drug prescriptions from both GPs and hospital 
specialists. Clinical laboratory data from tests 
ordered by both GPs and hospital specialists were 
available from central, eastern, and southern parts 
of the Netherlands. The overlapping catchment 
areas for the community pharmacies and the 
clinical laboratories result in a geographically 
defined subset of around 1 million patients. The 
PHARMO data network has been shown to be 
representative for the Dutch population.27-29
In the Netherlands, basic health insurance 
is mandatory for all residents, independent of 
age or employment status. Health insurance 
companies require clients to register with a 
community pharmacy, allowing for follow-up of 
medication history for each patient. Basic health 
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insurance fully reimburses most antidiabetic 
treatment options and covers diabetes-
monitoring programs implemented throughout 
the Netherlands, starting in 2001. Regular check-
ups are part of these monitoring programs. Since 
this is a retrospective study using anonymous 
data from the PHARMO network, approval by an 
ethics committee was not required.
Patient Selection
Patients were identified as users of either IDet 
(ATC A10AE05) or IGlar (ATC A10AE04). The first 
dispensing of long-acting insulin in the period 
January 1, 2004 to June 30, 2008 was defined as 
the cohort entry date, and the type of insulin 
treatment at this date was defined as the index 
treatment. Patients with an index treatment 
other than long-acting insulin as monotherapy 
were excluded, along with patients with missing 
HbA1c data (see Glycemic Control, below). A 
history of OADs dispensed at any time during 
the available history of patients was used to 
identify patients with T2D, since patients with 
T1D normally do not use OADs. Patients with 
T2D starting the use of IDet or IGlar were eligible 
for inclusion in the study if: they had been 
recorded in the database at least 1 year before 
cohort entry date; no insulin was dispensed to 
them in the year prior to cohort entry date; and 
they were followed up for at least 1 year. All 
patients fulfilling the above eligibility criteria 
were included in the “all eligible patients” 
(AEP) group. The “without treatment change” 
(WOTC) group consisted of a subgroup with no 
changes in insulin therapy prior to the HbA1c 
measurement at 1-year follow-up. Treatment 
changes included switches from basal to basal-
bolus, changes in type of basal insulin, switches 
to premixed insulin, and cessation of insulin 
therapy before the 1-year follow-up HbA1c 
measurement. If more than 6 months elapsed 
between two dispensings of insulin, insulin 
treatment was assumed to have ceased. Dose 
titrations and changes in concomitant OAD use 
were not viewed as changes in treatment. The 
treatment goal used for comparison was HbA1c 
<7%, in line with both Dutch GPs guidelines6 
and the new ADA/EASD consensus algorithm.7,8 
The WOTC group was included to enable a 
“clean” analysis without possible noise arising 
from treatment changes.
Glycemic Control
Baseline HbA1c was based on the measurement 
closest to the cohort entry date, but limited to a 
time window of 1 year before cohort entry date. 
Follow-up HbA1c at 12 months was obtained in 
the period between 9 and 15 months after cohort 
entry date using the HbA1c measurement closest 
to 12 months after cohort entry date. HbA1c 
goal attainment was defined as <7%, in line with 
ADA/EASD consensus and Dutch guidelines,6-8 
and was determined both at baseline and at 
12 months.
Daily Insulin Dose
To estimate the average daily insulin dose per 
type of insulin during the follow-up period, the 
total amount of insulin dispensed in the time 
interval from cohort entry date to the follow-up 
measurement of HbA1c was divided by the 
number of days between the cohort entry date 
and follow-up HbA1c measurements. Insulin 
dose measurements were excluded if there 
was only one insulin dispensing before the 
follow-up measurement or if there were more 
than 6 months (183 days) between the insulin 
dispensings before and after the follow-up 
measurement (assumed cessation of insulin 
therapy within these 6 months). For the AEP 
analysis all dispensed long-acting insulin up to 
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the point of treatment change was included in 
the calculation.
Body Weight
Changes in body weight were determined 
for the subset of patients for which weight 
assessments were registered both at baseline and 
at follow-up. These data were routinely collected 
during the diabetes-monitoring programs in 
primary care, but can only be accessed in one 
laboratory in the PHARMO network, limiting 
the number of patients for which these data 
were available.
Statistical Analyses
Data processing and statistical analyses were 
performed using SAS version 9.0 (SAS Institute 
Inc., Cary, NC, USA). Treatment changes were 
reported descriptively (numbers of patients 
and proportions). Patient characteristics 
were compared between IDet and IGlar users 
using descriptive statistics, Chi-squared tests, 
and two-sample Student’s t tests. Propensity 
scores were constructed using multivariate 
logistic models with the index treatment 
as the dependent variable and baseline 
characteristics as independent variables. Only 
relevant characteristics were included in the 
propensity scores (ie, only characteristics that 
were associated with the choice of treatment). 
Characteristics with a strong association to 
goal attainment were introduced as separate 
covariates in the multivariate models comparing 
outcomes, and were therefore excluded from 
the propensity scores. Characteristics that 
were evaluated as possible covariates were 
demographic characteristics, baseline HbA1c 
levels, and all known baseline comorbid 
conditions, based on medication use and 
hospitalizations, that were present in at least 
5% of the population. HbA1c goal attainment 
rates at follow-up were eventually compared 
between users of IDet and IGlar using logistic 
regression modeling, adjusted for age, gender, 
baseline HbA1c level, concomitant OAD use, 
and propensity score. The propensity score 
included prescriber initiating insulin therapy, 
year of starting insulin therapy, and prior OAD 
use. The validity of the propensity scores was 
checked by determining if the characteristics 
were similarly distributed in each of the 
quintiles of the propensity scores.
Daily average insulin dose was compared 
using linear regression of log-transformed data 
adjusting for age, gender, baseline HbA1c level, 
concomitant OAD use, and propensity score. 
Weight changes were compared using two-
sample Student’s t tests.
RESULTS
Population Size
Of the 22,496 patients using IDet or IGlar 
between January 1, 2004 and June 30, 2008 
there were 1872 insulin-naïve patients with 
T2D living in an area for which laboratory 
results were available (see Figure 1). For 929 
of those, HbA1c measurements at baseline and 
after 1 year were available. In all, 209 patients 
were excluded because they used a basal-bolus 
regimen. Of all eligible patients (AEP group, 
n=720) 252 started IDet use and 468 started 
IGlar use. At the time of the 1-year follow-up 
HbA1c measurement, 127 IDet users and 
292 IGlar users were without treatment 
change (WOTC group). During the patient 
selection process the proportion of IDet and 
IGlar users remained more or less the same, 
indicating that exclusion criteria affected 
users of both insulin types in a similar way. 
Moreover, most patients were excluded due 
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to the geographic area (living in an area 
without data capture). Thus, the potential 
selection bias is minimal and mainly affected 
by geography rather than access to care or 
different treatment paradigms.
Patient Characteristics
There were no significant differences between 
patient characteristics for IDet and IGlar users, 
either in the AEP analysis or the WOTC subgroup 
analysis, except for the higher proportion of 
male IGlar users in the AEP analysis and the 
significantly higher proportion of IDet users 
with heart failure (Table 1). However, the 
proportion of patients with heart failure was too 
small to be clinically relevant. Any differences 
in combinations of patient characteristics were 
balanced out in the following analyses using the 
propensity scores.
Glycemic Control
There was no difference in glycemic control 
(HbA1c levels) between IDet and IGlar users in 
both the AEP and the WOTC group, both at 
baseline (8.4%-8.6%) and after 1 year (7.4%-
7.5%) (Table 2). Further, there was no difference 
in goal attainment rates between IDet and IGlar 
in the AEP analysis at baseline (12.7% and 
11.3%) and at follow-up (33.3% and 35.7%). 
There was also no difference in goal attainment 
rates between IDet and IGlar in the WOTC 
analysis at baseline (8.7% and 11.0%) and at 
follow-up (31.5% and 35.3%). Multivariate 
comparison of IDet vs. IGlar users adjusting for 
age, gender, baseline HbA1c, concomitant OAD 
use, and propensity score showed no significant 
differences between goal attainment rates at 
follow-up, either in the AEP analysis (OR 0.81, 
95% CI: 0.57, 1.16) or in the WOTC analysis (OR 
0.75, 95% CI: 0.46, 1.24).
Figure 1. Patient selection. HbA1c=hemoglobin A1c; 
IDet=insulin detemir; IGlar=insulin glargine; OAD=oral 
antidiabetics.
Patients using IDet or IGlar  
between January 1, 2004 and June 30, 2008  
n=22,496
 
Type 2 diabetes based on OAD use in history  
n=14,664
5489 IDet 9175 IGlar
 
Patients with at least 1-year history and follow-up  
around first IDet or IGlar dispensing  
n=11,301
4287 IDet 7014 IGlar
 
Naïve insulin users  
n=5582
1649 IDet 3933 IGlar
 
Living in an area with overlapping drug dispensing and 
laboratory data  
n=1872
687 IDet 1185 IGlar
 
With HbA1c available during study period  
n=1347
544 IDet 803 IGlar
 
With HbA1c available at baseline and 1 year  
n=929
400 IDet 529 IGlar
 
Basal insulin only, excluding basal-bolus regimens  
(all eligible patients)  
n=720
252 IDet 468 IGlar
 
Without treatment change  
n=419
127 IDet 292 IGlar
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Table 1. Baseline characteristics.
Characteristics
All eligible patients Without treatment changes
IDet  
(n=252),  
n (%)
IGlar  
(n=468),  
n (%)
Chi-square  
test,  
P value
IDet  
(n=127),  
n (%)
IGlar  
(n=292),  
n (%)
Chi-square  
test,  
P value
Male gender 117 (46.4) 263 (56.2) 0.01 63 (49.6) 163 (55.8) 0.24
Age in years, mean (SD) 64.8 (12.1) 63.2 (12.8) 0.10* 65.7 (11.0) 63.4 (12.1) 0.06*
Prescriber:
 GP 143 (56.7) 237 (50.6) 0.28 81 (±63.8) 162 (±55.5) 0.21
 Internist 99 (39.3) 207 (44.2) 41 (32.3) 121 (41.4)
 Other specialist 10 (4.0) 24 (5.1) 5 (3.9) 9 (3.1)
Concomitant OAD use:†
 None 21 (8.3) 32 (6.8) 0.76 11 (8.7) 9 (3.1) 0.11
 Metformin 44 (17.5) 102 (21.8) 21 (16.5) 76 (26.0)
 Metformin + SU 137 (54.4) 240 (51.3) 76 (59.8) 155 (53.1)
 Metformin + SU + TZD 6 (2.4) 15 (3.2) 2 (1.6) 11 (3.8)
 Metformin + TZD 6 (2.4) 14 (3.0) 4 (3.1) 9 (3.1)
 SU 36 (14.3) 58 (12.4) 12 (9.4) 29 (9.9)
 SU + TZD 2 (0.8) 4 (0.9) 1 (0.8) 2 (0.7)
 TZD 0 (0) 2 (0.4) 0 (0) 1 (0.3)
 Other 0 (0) 1 (0.2) 0 (0) 0 (0)
Prior OAD use:‡
 Any 246 (97.6) 454 (97.0) 0.63 126 (99.2) 286 (97.9) 0.35
 Metformin 216 (85.7) 405 (86.5) 0.76 110 (86.6) 261 (89.4) 0.41
 SU 216 (85.7) 408 (87.2) 0.58 109 (85.8) 250 (85.6) 0.95
 TZD 64 (25.4) 137 (29.3) 0.27 34 (26.8) 90 (30.8) 0.40
Comedications:§
 Antihypertensives 174 (69.0) 322 (68.8) 0.95 90 (70.9) 202 (69.2) 0.73
 Platelet inhibitors 100 (39.7) 187 (40.0) 0.94 53 (41.7) 125 (42.8) 0.84
 Nitrates 35 (13.9) 55 (11.8) 0.41 17 (13.4) 32 (11.0) 0.48
 Digoxin 11 (4.4) 21 (4.5) 0.94 5 (3.9) 13 (4.5) 0.81
Comorbidities:◊
 Ischemic heart disease 7 (2.8) 21 (4.5) 0.26 4 (3.1) 10 (3.4) 0.89
 Heart failure 5 (2.0) 2 (0.4) 0.04 3 (2.4) 1 (0.3) 0.05
 Cerebral vascular disease 4 (1.6) 2 (0.4) 0.10 2 (1.6) 1 (0.3) 0.17
 Peripheral vascular disease 0 (0) 1 (0.2) 0.46 0 (0) 1 (0.3) 0.51
Number of hospitalizations:¶
 None 179 (71.0) 362 (77.4) 0.16 94 (74.0) 235 (80.5) 0.33
 1 42 (16.7) 64 (13.7) 19 (15.0) 32 (11.0)
 ≥2 31 (12.3) 42 (9.0) 14 (11.0) 25 (8.6)
*Student’s t test.
†OAD categories are mutually exclusive.
‡Metformin SU and TZD may have been used simultaneously.
§Based on drug dispensings in the year before start insulin.
◊Based on hospitalizations in the year before start insulin.
¶Hospitalizations for any cause in the year before start of insulin.
GP=general practitioner; IDet=insulin detemir; IGlar=insulin glargine; OAD=oral antidiabetics; SU=sulfonylurea; 
TZD=thiazolidinedione.
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Daily Insulin Dose
There were no significant differences in 
insulin utilization, measured by median daily 
insulin dose, between IDet and IGlar users 
in the WOTC analysis; 24.7 IU/day for IDet 
and 25.3 IU/day for IGlar, which was not 
significantly different (P=0.70) (Table 3). Dose 
calculations in the AEP analysis were limited 
to the period leading up to the treatment 
change. Since not all patients had at least 
two dispensings of the initial basal insulin 
within 6 months of each other before the 
treatment change, the number of patients 
with a dose calculation in the AEP group was 
limited to 75% of IDet users, and 83% of IGlar 
users. The doses of patients that switched 
treatment were marginally higher than those 
of patients that had no treatment changes, but 
ultimately the daily dose was not significantly 
different between IDet and IGlar users in the 
AEP analysis.
Table 2. Glycemic control.
Patients
All eligible patients Without treatment changes
IDet,  
(n=252)
IGlar, 
(n=468) P value*
IDet,  
(n=127)
IGlar, 
(n=292) P value*
HbA1c at baseline, mean (SD) 8.4 (1.4) 8.5 (1.4) 0.27 8.4 (1.3) 8.6 (1.4) 0.22
HbA1c at follow-up, mean (SD) 7.5 (1.0) 7.4 (1.0) 0.56 7.4 (0.9) 7.4 (0.9) 0.60
No. at goal at baseline, % (n) 12.7 (32) 11.3 (53) 0.59 8.7 (11) 11.0 (32) 0.48
No. at goal at 1 year, % (n) 33.3 (84) 35.7 (167) 0.53 31.5 (40) 35.3 (103) 0.45
No. at goal at 1 year, unadjusted 
OR (95% CI)
0.90 (0.65, 1.24) 0.53 0.84 (0.54, 1.32) 0.45
No. at goal at 1 year adjusted  
OR (95% CI)†
0.81 (0.57, 1.16) 0.25 0.75 (0.46, 1.24) 0.26
Goal attainment = HbA1c <7%.
*Unadjusted Student’s t test (HbA1c), or unadjusted Chi-square test (at goal), or logistic regression (OR).
†Logistic regression model adjusting for age, gender, baseline HbA1c, concomitant oral antidiabetics use, and propensity score.
CI=confidence interval; IDet=insulin detemir; IGlar=insulin glargine; OR=odds ratio.
Table 3. Median daily dose during follow-up.
Patients
Daily IDet dose (IU/day) Daily IGlar dose (IU/day)
P valuen Median (IQR) n Median (IQR)
All eligible patients 190 26.8 (17.3-39.8) 389 27.4 (17.8-39.0) 0.76
Without treatment changes 127 24.7 (16.2-37.8) 292 25.3 (16.8-35.6) 0.70
Doses were compared using linear regression of log-transformed doses adjusting for age, gender, concomitant oral antidiabetic 
use, propensity score, and baseline HbA1c. Analysis of all eligible patients includes dispensings up to treatment change only.
IQR=interquartile range, encompassing 50% of all data (25%-75%); IDet=insulin detemir; IGlar=insulin glargine.
IU=International Unit.
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Weight Change
Weight measurements at baseline and 
follow-up were available for approximately 20% 
of all patients. Weight changes show slightly 
higher weight gain among IGlar users than 
among IDet users, but these differences were not 
significant (Table 4).
DISCUSSION
RCTs have very high internal validity; 
however, RCTs may have low external validity 
(generalizabilty) due to strict inclusion and 
exclusion criteria (selected subpopulations), 
specialized treatment settings, frequent visits, 
and monitoring. The strength of this study is 
that it reflects insulin use in patients with T2D in 
daily routine clinical practice, without the strict 
inclusion criteria and controlled environment of 
clinical trials.
This study shows that in daily clinical practice 
in the Netherlands, IDet and IGlar provide 
similar glycemic control at similar daily insulin 
dose after adjustment for differences in patient 
characteristics. This is hardly surprising as RCTs 
previously have demonstrated no differences 
in glycemic control.19,20,22,24,30,31 However, it is 
interesting to go beyond the “efficacy” results 
obtained in RCTs and examine the “effectiveness” 
observed in a real-life setting as these outcomes 
are essentially what physicians are dealing with 
on a daily basis.
A baseline HbA1c at 8.4%-8.5% and a 
corresponding baseline target rate as low as 
11%-13% when initiating insulin treatment 
(Table 2) may indicate that insulin therapy in 
the study population was initiated too late. This 
hypothesis is consistent with the results from a 
US retrospective study which found that patients 
with T2D with inadequate glycemic control 
(HbA1c ≥8%) waited for approximately 5 years 
before insulin therapy was initiated.32 A similar 
study based on UK data demonstrated that 50% 
of patients with T2D delayed insulin for almost 
5 years after failure of glycemic control (HbA1c 
≥8%).33 A delay in timely insulin initiation is not 
trivial and has been documented to reduce life 
expectancy and compromise quality of life.34
A mean HbA1c at 7.4% and a corresponding 
target rate of 32%-35% after 1 year in the WOTC 
analysis may indicate the basal insulin analogs 
were not titrated aggressively enough (Table 2). 
The AEP analysis shows similar results with a 
follow-up HbA1c at 7.4%-7.5% and 33%-36% 
reaching HbA1c target after 1 year. This suggests 
Table 4. Weight assessments.
Patients
IDet IGlar
P valuen Mean (SD) n Mean (SD)
All eligible patients:
 Baseline, kg 50 81.3 (13.3) 90 86.4 (±8.1)
 1 year, kg 50 81.5 (14.6) 90 87.6 (18.2)
 Weight change, kg 50 0.2 (4.7) 90 1.2 (4.4) 0.20
Without treatment changes:
 Baseline, kg 25 84.0 (14.3) 65 87.5 (19.7)
 1 year, kg 25 84.5 (51.3) 65 88.6 (19.4)
 Weight change, kg 25 0.4 (3.7) 65 1.1 (4.5) 0.50
Weight changes were compared using Student’s t test.
IDet=insulin detemir; IGlar=insulin glargine.
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that observed changes in treatment do not 
necessarily result in increased goal attainment. 
Similar trends have been documented in a 
UK-based real-life study.35 In this study the mean 
HbA1c prior to therapy was 9.9%. Although the 
patients experienced a significant reduction of 
1.3 percentage points in HbA1c, 73% still had 
HbA1c ≥7.5% 6 months after insulin initiation, 
which could indicate a suboptimal insulin dose. 
The hypothesis that insulin doses may be too low 
is supported by the finding that the basal insulin 
doses (see Table 4) were well below the 40 units 
as recommended by World Health Organization 
(WHO) to be defined as the defined daily dose 
(DDD). However, as insulin dose is dependent on 
individual patient characteristics such as weight, 
this value has to be used as a proxy.
Possible explanations for lack of titration to 
target may be that the patients have a history 
of severe hypoglycemia and/or advanced 
microvascular or macrovascular complications, 
or extensive comorbid conditions. The ADA/
EASD consensus algorithm acknowledge that the 
stringent HbA1c targets are not appropriate for 
all patients and that clinical judgment should be 
used to balance risk and benefits of intensified 
treatments.8 Similarly, despite the target HbA1c 
level of 7% of the Dutch diabetes type 2 guideline 
from 1999,36 HbA1c levels up to 8% were also 
called acceptable. Patients and physicians may 
therefore have been satisfied with the status 
quo, possibly because they were not fully aware 
of the potential long-term complications caused 
by elevated HbA1c. Unfortunately, data on 
hypoglycemic events were not available in the 
data. Furthermore, many patients might benefit 
from a basal-bolus regimen instead of a basal 
insulin-only regimen. The Dutch guidelines6 
recommend increasing the dosing frequency or 
the use of premixed insulin before considering 
basal-bolus therapy. The study period may 
have been too short to allow improved goal 
attainment rates as a result of such treatment 
changes to show a clear difference between the 
AEP and WOTC results.
Even though many patients are not treated 
to target using the general HbA1c goal of <7% 
as recommended by ADA/EASD, an even lower 
HbA1c goal of <6.5% has been suggested by 
other professional diabetes organizations such 
as International Diabetes Federation (IDF).37 The 
key argument for ADA/EASD not decreasing the 
target HbA1c recommendation is the exaggerated 
risk of hypoglycemia. However, in recent years, 
this risk has been greatly reduced in patients 
with type 1 diabetes, and even in patients 
with T2D with availability of the new insulin 
analogs.11,14,38 It might be unrealistic to expect 
healthcare providers to do better than what is 
achieved in a clinical trial setting. However, 
setting a lower target of 6.5% might mean that 
clinicians would perhaps intervene sooner.39 
Future clinical studies focusing on reasons 
for lack of treatment-to-target might help to 
improve glycemic control in clinical practice.
An inherent limitation of any observational 
study is the sensitivity to bias, and the possibility 
that not all confounders may be available for 
adjustments in multivariate models. For example, 
diet and exercise are known to influence both 
glycemic control and weight gain to a large 
extent,40 but these data were not available in the 
database. Therefore the possibility of bias cannot 
be excluded. However, there are no compelling 
reasons to assume these factors differ between 
the treatment groups. The analyses were 
adjusted for the most important determinants 
of goal attainment, ie, baseline HbA1c, as well 
as age and gender. Furthermore, indication 
bias was eliminated by adjusting for propensity 
scores. Characteristics that were ultimately 
included in the propensity scores were prior 
use of metformin, sulfonylurea derivatives or 
thiazolidinediones, prescriber initiating insulin 
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therapy, and calendar year in which insulin 
treatment was initiated. As matching based on 
propensity scores would have resulted in a loss of 
patients and thus power, it was decided to adjust 
for the propensity scores instead. Within the 
quintiles of the propensity scores, characteristics 
were equally distributed in each of the treatment 
groups, showing that the propensity score was 
valid as a method of this adjustment.
Insulin dosing had to be estimated from 
the total amount of insulin dispensed during 
the period leading up to the follow-up HbA1c 
assessment, as insulin dosing is flexible and 
therefore not recorded in the pharmacy 
records. For some patients in the AEP analysis, 
the amount or frequency of dispensings 
was insufficient to allow dose calculations, 
because a change in therapy was made early 
on in the follow-up period. The AEP analyses 
should therefore be interpreted with caution. 
For the WOTC analyses it was assumed that 
errors in dose calculation resulting from the 
proportion of insulin that is not actually 
used but discarded (for example if exposed to 
high temperatures) is similar for both insulin 
types. All patients used prefilled pens and 
hence there were no differences in packaging 
or administration methods that might have 
caused differences in the proportion of 
dispensed insulin that was actually used, which 
in turn could have introduced differences in 
accuracy of dose calculations. Furthermore, 
insulin dose requirements are correlated with 
weight so weight differences are important 
for interpretation of dosing results. Observed 
weight differences at baseline were limited 
(WOTC IDet 84 kg, IGlar 88 kg), which makes 
it unlikely to be an important factor in the dose 
comparisons. Although weight data are limited 
to 20% of the population, they were gathered 
as part of a routine monitoring program in a 
specific geographical area within the PHARMO 
catchment area, which limits the possibility of 
bias in these data. Although the sample size was 
too small to show any significant difference, 
the data do support the trend observed in other 
studies,14,20,23 that weight gain is less among 
patients using IDet than among patients using 
IGlar, the difference being around 1 kg.
CONCLUSIONS
As documented in previous RCTs there was 
no significant difference between users of IDet 
and IGlar with respect to glycemic control 
and insulin dose in a real-life setting in the 
Netherlands. However, the observation that as 
few as 11% were on target when initiating insulin 
treatment may indicate than insulin therapy is 
initiated too late. Moreover, the observation that 
only 32%-35% reach HbA1c target after 1 year 
may indicate the basal insulin analogs are not 
titrated intensively enough.
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